Karyopharm Therapeutics CEO Michael Kauffman's 2020 pay jumps 22% to $3.9M
Karyopharm Therapeutics reports 2020 executive compensation
By ExecPay News
Published: April 7, 2021
Karyopharm Therapeutics reported fiscal year 2020 executive compensation information on April 7, 2021.
In 2020, three executives at Karyopharm Therapeutics received on average a compensation package of $3.3M, a 49% increase compared to previous year.
Average pay of disclosed executives at Karyopharm Therapeutics
Michael G. Kauffman, Chief Executive Officer, received $3.9M in total, which increased by 22% compared to 2019. 49% of Kauffman's compensation, or $1.9M, was in option awards. Kauffman also received $349K in non-equity incentive plan, $626K in salary, $1M in stock awards, as well as $12K in other compensation.
Sharon Shacham, Chief Scientific Officer, received a compensation package of $3.7M, which increased by 22% compared to previous year. 52% of the compensation package, or $1.9M, was in option awards.
Michael Mason, Chief Financial Officer, earned $2.3M in 2020, a 137% increase compared to previous year.
Related executives
You may also like
Source: SEC filing on April 7, 2021.